ArticleTherapeutic advances in urology2013
Experience with degarelix in the treatment of prostate cancer.
Article in Therapeutic advances in urology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 4 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- A systematic review and meta-analysis of cardiovascular disease risk with degarelix and GnRH agonists in prostate cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Pooled it
- Clinical recommendations in the management of advanced prostate cancer: International Gastrointestinal, Liver and Uro-oncology (IGILUC 2019) experts.World journal of urology · 2021Guideline
- Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses.Arteriosclerosis, thrombosis, and vascular biology · 2020Pooled it
- [Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer].Der Urologe. Ausg. A · 2019Pooled it
- Safety, Pharmacokinetic and Pharmacodynamic Evaluation of Teverelix for the Treatment of Hormone-Sensitive Advanced Prostate Cancer: Phase 2 Loading-Dose-Finding Studies.Medicina (Kaunas, Lithuania) · 2023Trial
- Recent advances in hormone-based biopharmaceuticals for cancer therapy.Journal of the Egyptian National Cancer Institute · 2026Review
- Tumor Lysis Syndrome Induced by Hormonal Therapy in Metastatic Prostate Cancer: A Case Report.Cureus · 2025Article
- Article
- Sex-dependent endocrine and cellular effects of the GnRH antagonist degarelix in rabbits and cell models.American journal of translational research · 2025Article
- The Effect of Androgen Deprivation Therapy on the Cardiovascular System in Advanced Prostate Cancer.Medicina (Kaunas, Lithuania) · 2024Review
- A Practical Guide to Relugolix: Early Experience With Oral Androgen Deprivation Therapy.The oncologist · 2023Article
- Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Dysfunctional Lipid Metabolism-The Basis for How Genetic Abnormalities Express the Phenotype of Aggressive Prostate Cancer.Cancers · 2023Review
- Cardiovascular Toxicity of Androgen Deprivation Therapy.Current cardiology reports · 2021Review
- Cardiovascular risks and toxicity - The Achilles heel of androgen deprivation therapy in prostate cancer patients.Biochimica et biophysica acta. Reviews on cancer · 2020Review
- Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China.Asian journal of urology · 2020Article
- Lymph nodes as barriers to T-cell rejuvenation in aging mice and nonhuman primates.Aging cell · 2019Article
- Effectiveness of Subcutaneously Administered Leuprolide Acetate to Achieve Low Nadir Testosterone in Prostate Cancer Patients.Reviews in urology · 2018Article
- Retrospective Analysis of Patients With Prostate Cancer Initiating GnRH Agonists/Antagonists Therapy Using a German Claims Database: Epidemiological and Patient Outcomes.Frontiers in oncology · 2018Article
- GnRH Antagonist: a New and an Effective Way of Treatment of Advanced Prostate Cancer.Indian journal of surgical oncology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Degarelix is a gonadotrophin-releasing hormone (GnRH) antagonist for the first-line treatment of androgen-dependent advanced prostate cancer. It has a direct mechanism of action that blocks the action of GnRH on the pituitary with no initial surge in gonadotrophin or testosterone levels. Degarelix is the most extensively studied and widely available GnRH antagonist worldwide. Clinical studies have demonstrated similar efficacy to the GnRH agonist leuprolide in achieving testosterone suppression in patients with prostate cancer. However, degarelix produces a faster suppression of testosterone and prostate-specific antigen (PSA), with no testosterone surge or microsurges, thus preventing the risk of clinical flare in advanced disease. Clinical trials have demonstrated that degarelix can offer improved disease control when compared with a GnRH agonist in terms of superior PSA progression-free survival (suggesting that degarelix likely delays progression to castration-resistant disease), and a more significant impact on bone serum alkaline phosphatase and follicle-stimulating hormone. Degarelix is generally well tolerated, with no reports of systemic allergic reactions in any clinical studies. In conclusion, degarelix offers clinicians a rational first-line hormonal monotherapy option for the management of advanced prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.